Medicxi Unveils, Medicxi, a prominent European life sciences investment firm, has recently introduced its latest fund, Medicxi IV, with a substantial value of $400 million. This fund is dedicated to supporting companies with clear and innovative product visions, aiming to deliver transformative therapies that can significantly benefit patients’ lives.
Medicxi’s previous investments have already resulted in the development of several successful drugs, both in the market and at late-stage development. These include noteworthy medications like Daratumumab (Genmab/Johnson & Johnson), Blincyto (Amgen), Alunbrig (Takeda), Voquezna (Phathom Pharmaceuticals), and obicetripib (New Amsterdam Pharma). Additionally, some of Medicxi’s assets have been acquired by global pharmaceutical giants such as Incyte, Gilead Sciences, and Eli Lilly in the past year.
Francesco De Rubertis, co-founder and partner at Medicxi, emphasized their mission to support innovative entrepreneurs by providing crucial capital, expertise, and experience to bridge the gap to pharmaceutical success. He expressed gratitude to their investors for backing Medicxi’s unique asset-centric strategy and proprietary platform for value creation.
Nick Williams, another partner at Medicxi, shared their excitement to continue developing exceptional product visions into valuable assets that attract leading global pharmaceutical companies.
Giovanni Mariggi, partner at Medicxi, highlighted their commitment to collaborating with top scientists and clinicians to establish asset-focused companies based on deep domain expertise. With the support of their extensive network of drug developers, they aim to accelerate the development of novel therapies to benefit patients worldwide.
Medicxi Unveils
